What is the risk of ovarian and endometrial cancer in women who carry a pathogenic ATM mutation, and what surveillance or risk‑reduction strategies are recommended?

ATM Mutation and Gynecologic Cancer Risk

Women with heterozygous pathogenic ATM mutations have a modestly increased risk of ovarian cancer (2-3 times the general population risk) but routine risk-reducing salpingo-oophorectomy is NOT recommended. 1

Ovarian Cancer Risk

The absolute risk elevation for ovarian cancer in ATM heterozygotes is 2-3 fold above baseline, which translates to a moderate rather than high-risk category 2, 3. This stands in stark contrast to BRCA1/2 carriers who face substantially higher risks warranting prophylactic surgery 4.

Key evidence points:

• Multiple studies confirm ATM pathogenic variants are detected more frequently in ovarian cancer cases compared to healthy controls 3
• However, the magnitude of risk increase does not meet the threshold that justifies routine prophylactic oophorectomy 1
• The 2025 ACMG guidelines explicitly state that data does not support routine RRSO for ATM carriers 1

Endometrial Cancer Risk

The evidence regarding endometrial cancer risk in ATM carriers is limited and conflicting:

• One older study (2008) suggested ATM Ser707Pro carriers had elevated endometrial cancer risk (HR 2.7) 5, but this was a single missense variant in exploratory analysis
• More recent data (2020) indicates ATM mutations in endometrial tumors may actually be associated with better prognosis and longer overall survival 6
• The prognostic significance appears related to tumor biology (increased immune infiltration, higher tumor mutational burden) rather than germline predisposition 6

There is insufficient evidence to establish a clinically significant germline ATM-associated endometrial cancer risk requiring specific surveillance.

Recommended Management Strategy

When to Consider Risk-Reducing Surgery

RRSO should only be discussed in ATM carriers under these specific circumstances: 1

1. Strong family history of ovarian cancer (multiple affected relatives, particularly first-degree)
2. Gynecological surgery already planned for other medical indications (e.g., symptomatic fibroids, endometriosis)
3. Patient preference after thorough shared decision-making regarding the modest risk elevation versus surgical risks and consequences

Surveillance Approach

Since prophylactic surgery is not routinely indicated, no specific enhanced gynecologic surveillance protocol is established for ATM carriers beyond standard population screening recommendations 1.

Important caveat: The ACMG guidelines emphasize that management decisions should incorporate comprehensive risk assessment using tools like CanRisk that account for family history, not mutation status alone 1. An ATM carrier with multiple affected relatives may warrant different counseling than an isolated carrier.

Common Pitfalls to Avoid

• Do not equate ATM with BRCA1/2 risk levels - the gynecologic cancer risks are substantially lower and do not justify the same aggressive interventions used in hereditary breast-ovarian cancer syndrome 1, 4
• Do not recommend RRSO based solely on ATM carrier status without considering family history context 1
• Recognize that some ATM variants may not confer increased cancer risk at all - for example, the c.103C>T variant showed lower rates in breast cancer cases than controls 3

The evidence strongly supports a conservative, family history-informed approach rather than routine prophylactic surgery for gynecologic cancer risk reduction in ATM heterozygotes.